Neurocrine Biosciences, Inc.(NBIX)Earnings, Financials & Key Ratios

NBIX•NASDAQ

$149.59

$15.01B mkt cap·32.0× P/E·Price updated May 7, 2026

SectorHealthcare IndustrySpecialty & Generic Pharma Sub-IndustryTherapy-focused branded biopharma

AboutNeurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.Show more

Revenue$2.86B+21.4%
EBITDA$649M+8.6%
Net Income$479M+40.2%
EPS (Diluted)4.67+41.9%
Gross Margin98.18%-0.4%
EBITDA Margin22.7%-10.6%
Operating Margin21.64%-10.6%
Net Margin16.73%+15.5%
ROE16.38%+15.7%
ROIC16.1%-1.8%
Debt/Equity0.13-27.4%

Analysis→Technical→

NBIX Key Insights

Neurocrine Biosciences, Inc. (NBIX) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓FCF machine: 26.2% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 22.3%
✓Healthy 5Y average net margin of 12.5%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

NBIX Price & Volume

Neurocrine Biosciences, Inc. (NBIX) stock price & volume — 10-year historical chart

Loading chart...

NBIX Growth Metrics

Neurocrine Biosciences, Inc. (NBIX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years64.45%

5 Years22.29%

3 Years24.32%

TTM28.59%

Profit CAGR

10 Years-

5 Years3.28%

3 Years45.77%

TTM118.64%

EPS CAGR

10 Years-

5 Years2.34%

3 Years44.12%

TTM120%

Return on Capital

10 Years3.4%

5 Years13.62%

3 Years16.14%

Last Year17.44%

NBIX Recent Earnings

Neurocrine Biosciences, Inc. (NBIX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 6/12 qtrs (50%)●Beat Revenue 8/12 qtrs (67%)

Q2 2026Latest

May 5, 2026

EPS

$1.94

Est $1.68

+15.5%

Revenue

$815M

Est $768M

+6.0%

Q1 2026

Feb 11, 2026

EPS

$1.88

Est $1.80

+4.4%

Revenue

$806M

Est $790M

+1.9%

Q4 2025

Oct 28, 2025

EPS

$2.04

Est $1.58

+29.1%

Revenue

$795M

Est $807M

-1.5%

Q3 2025

Jul 30, 2025

EPS

$1.06

Est $0.98

+8.2%

Revenue

$688M

Est $746M

-7.9%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 5, 2026	$1.94vs $1.68+15.5%	$815Mvs $768M+6.0%
Q1 2026	Feb 11, 2026	$1.88vs $1.80+4.4%	$806Mvs $790M+1.9%
Q4 2025	Oct 28, 2025	$2.04vs $1.58+29.1%	$795Mvs $807M-1.5%
Q3 2025	Jul 30, 2025	$1.06vs $0.98+8.2%	$688Mvs $746M-7.9%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
INVAInnoviva, Inc.Direct Competitor	1.93B	22.80	6.91	18.52%	118.91%	46.47%	0.23
ACADACADIA Pharmaceuticals Inc.Direct Competitor	3.86B	22.57	9.85	11.87%	34.3%	35.65%	0.04
PTCTPTC Therapeutics, Inc.Direct Competitor	5.35B	64.49	8.29	114.51%	-22.58%
RAREUltragenyx Pharmaceutical Inc.Direct Competitor	2.57B	26.13	-4.48	20.13%	-91.03%	-6.08%
FOLDAmicus Therapeutics, Inc.Direct Competitor	4.55B	14.49	-164.85	20.05%	-4.27%	-12.02%	1.76
PRGOPerrigo Company plcDirect Competitor	1.61B	11.72	-1.14	-2.75%	-43.5%	-50.65%	1.35
ALKSAlkermes plcProduct Competitor	5.9B	35.40	24.76	-5.25%	9.78%	8.82%	0.04
SUPNSupernus Pharmaceuticals, Inc.Product Competitor	3.01B	52.28	-76.88	8.63%	-3.74%	-2.73%	0.04

Compare NBIX vs Peers

Neurocrine Biosciences, Inc. (NBIX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs INVA

Most directly comparable listed peer for NBIX.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare NBIX against a more recognizable public peer.

Peer Set

Compare Top 5

vs INVA, ACAD, PTCT, RARE

NBIX Income Statement

Neurocrine Biosciences, Inc. (NBIX) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	161.63M	451.2M	788.1M	1.05B	1.13B	1.49B	1.89B	2.36B	2.86B	3.1B
Revenue Growth %	977.51%	179.16%	74.67%	32.71%	8.38%	31.34%	26.76%	24.81%	21.45%	28.59%
Cost of Goods Sold	1.25M	4.9M	7.4M	10.1M	14.3M	23.2M	39.7M	34M	52.1M	56.7M
COGS % of Revenue	0.78%	1.09%	0.94%	0.97%	1.26%	1.56%	2.1%	1.44%	1.82%	-
Gross Profit	160.37M▲ 0%	446.3M▲ 178.3%	780.7M▲ 74.9%	1.04B▲ 32.7%	1.12B▲ 8.1%	1.47B▲ 30.9%	1.85B▲ 26.1%	2.32B▲ 25.7%	2.81B▲ 21.0%	3.05B▲ 0%
Gross Margin %	99.22%	98.91%	99.06%	99.03%	98.74%	98.44%	97.9%	98.56%	98.18%	98.17%
Gross Profit Growth %	969.15%	178.29%	74.93%	32.68%	8.05%	30.94%	26.06%	25.65%	20.98%	-
Operating Expenses	291.73M	409.5M	708.4M	872.8M	1.02B	1.22B	1.6B	1.75B	2.19B	2.26B
OpEx % of Revenue	180.5%	90.76%	89.89%	83.45%	89.7%	81.72%	84.6%	74.33%	76.54%	-
Selling, General & Admin	169.91M	248.93M	354.1M	433.3M	583.3M	752.7M	887.6M	1.01B	1.16B	1.2B
SG&A % of Revenue	105.12%	55.17%	44.93%	41.43%	51.46%	50.56%	47.04%	42.76%	40.42%	-
Research & Development	91.83M	155.8M	200M	275M	328.1M	463.8M	565M	731.1M	1.02B	1.05B
R&D % of Revenue	56.81%	34.53%	25.38%	26.29%	28.95%	31.15%	29.94%	31.04%	35.51%	-
Other Operating Expenses	30M	4.8M	154.3M	164.5M	105.3M	0	143.9M	12.5M	17.4M	1.3M
Operating Income	-131.36M▲ 0%	36.8M▲ 128.0%	72.3M▲ 96.5%	163M▲ 125.4%	102.5M▼ 37.1%	249M▲ 142.9%	250.9M▲ 0.8%	570.5M▲ 127.4%	619.1M▲ 8.5%	788.9M▲ 0%
Operating Margin %	-81.27%	8.16%	9.17%	15.58%	9.04%	16.73%	13.3%	24.22%	21.64%	25.43%
Operating Income Growth %	10.86%	128.01%	96.47%	125.45%	-37.12%	142.93%	0.76%	127.38%	8.52%	-
EBITDA	-128.96M	40.82M	79.75M	171.6M	113.4M	264.6M	272.2M	597.6M	649.2M	811.4M
EBITDA Margin %	-79.79%	9.05%	10.12%	16.41%	10%	17.77%	14.42%	25.37%	22.7%	26.15%
EBITDA Growth %	11.59%	131.66%	95.36%	115.17%	-33.92%	133.33%	2.87%	119.54%	8.63%	55.05%
D&A (Non-Cash Add-back)	2.4M	4.02M	7.45M	8.6M	10.9M	15.6M	21.3M	27.1M	30.1M	22.5M
EBIT	-123.02M	52.3M	78.5M	139.5M	127.2M	249M	394.8M	612.6M	636.5M	665.3M
Net Interest Income	-19.52M	-30.5M	-32M	-32.8M	-25.8M	4.1M	-4.6M	-35.6M	90.3M	0
Interest Income	0	0	0	0	0	11.2M	0	91M	90.3M	0
Interest Expense	19.52M	30.53M	32M	32.8M	25.8M	7.1M	4.6M	126.6M	0	0
Other Income/Expense	-11.18M	-15.05M	-25.8M	-56.3M	-1.1M	-35.1M	81.2M	-84.5M	86.3M	148.6M
Pretax Income	-142.54M▲ 0%	21.84M▲ 115.3%	46.5M▲ 112.9%	106.7M▲ 129.5%	101.4M▼ 5.0%	213.9M▲ 110.9%	332.1M▲ 55.3%	486M▲ 46.3%	705.4M▲ 45.1%	937.5M▲ 0%
Pretax Margin %	-88.19%	4.84%	5.9%	10.2%	8.95%	14.37%	17.6%	20.63%	24.66%	30.22%
Income Tax	0	730K	9.5M	-300.6M	11.8M	59.4M	82.4M	144.7M	226.8M	268.9M
Effective Tax Rate %	0%	3.34%	20.43%	-281.72%	11.64%	27.77%	24.81%	29.77%	32.15%	28.68%
Net Income	-142.54M▲ 0%	21.11M▲ 114.8%	37M▲ 75.3%	407.3M▲ 1000.8%	89.6M▼ 78.0%	154.5M▲ 72.4%	249.7M▲ 61.6%	341.3M▲ 36.7%	478.6M▲ 40.2%	668.6M▲ 0%
Net Margin %	-88.19%	4.68%	4.69%	38.94%	7.9%	10.38%	13.23%	14.49%	16.73%	21.55%
Net Income Growth %	-1.03%	114.81%	75.26%	1000.81%	-78%	72.43%	61.62%	36.68%	40.23%	118.64%
Net Income (Continuing)	-142.54M	21.11M	37M	407.3M	89.6M	154.5M	249.7M	341.3M	478.6M	668.6M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-1.62▲ 0%	0.22▲ 113.6%	0.39▲ 77.3%	4.16▲ 966.7%	0.92▼ 77.9%	1.56▲ 69.6%	2.47▲ 58.3%	3.29▲ 33.2%	4.67▲ 41.9%	6.47▲ 0%
EPS Growth %	0.61%	113.58%	77.27%	966.67%	-77.88%	69.57%	58.33%	33.2%	41.95%	120%
EPS (Basic)	-1.62	0.22	0.40	4.37	0.95	1.61	2.56	3.40	4.81	-
Diluted Shares Outstanding	88.09M	95.4M	95.73M	97.8M	97.9M	98.9M	101M	103.7M	102.5M	103.4M
Basic Shares Outstanding	87.99M	95.4M	91.63M	93.1M	94.6M	95.8M	97.7M	100.4M	99.5M	100.5M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

NBIX Balance Sheet

Neurocrine Biosciences, Inc. (NBIX) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	554.92M	737.78M	831M	1.02B	972.8M	1.45B	1.61B	1.72B	2.52B	2.44B
Cash & Short-Term Investments	515.93M	650.91M	670.5M	801M	711.3M	989.3M	1.03B	1.08B	1.48B	1.32B
Cash Only	254.71M	141.71M	112.3M	187.1M	340.8M	262.9M	251.1M	233M	713M	266.5M
Short-Term Investments	261.22M	509.2M	558.2M	613.9M	370.5M	726.4M	780.5M	843.1M	767.4M	1.05B
Accounts Receivable	31.13M	57.41M	126.6M	157.1M	185.5M	350M	439.3M	479.1M	686.8M	768.1M
Days Sales Outstanding	70.29	46.44	58.63	54.83	59.73	85.81	84.97	74.25	87.64	81.73
Inventory	1.02M	10.86M	17.3M	28M	30.5M	35.1M	38.3M	57.4M	69M	64.5M
Days Inventory Outstanding	298.05	809.26	853.31	1.01K	778.5	552.22	352.13	616.21	483.4	417.95
Other Current Assets	6.84M	18.59M	16.6M	30.1M	45.5M	79.1M	97.8M	112.1M	286.5M	287.3M
Total Non-Current Assets	262.67M	255.37M	475M	718.5M	1.1B	915.2M	1.64B	1.99B	2.11B	2.47B
Property, Plant & Equipment	10.81M	33.87M	116.2M	127.4M	155.8M	145.6M	347.3M	592M	545.2M	538M
Fixed Asset Turnover	14.95x	13.32x	6.78x	8.21x	7.28x	10.22x	5.43x	3.98x	5.25x	5.56x
Goodwill	0	0	0	0	0	0	0	5.7M	0	0
Intangible Assets	0	0	0	0	0	37.2M	35.5M	36.5M	0	0
Long-Term Investments	247.36M	216.03M	355.6M	265.3M	624.4M	401.5M	849.4M	864.3M	1.18B	2.41B
Other Non-Current Assets	4.5M	5.48M	3.2M	6.4M	4.4M	25M	49.6M	9.8M	59.5M	2.5B
Total Assets	817.59M▲ 0%	993.15M▲ 21.5%	1.31B▲ 31.5%	1.73B▲ 32.8%	2.07B▲ 19.5%	2.37B▲ 14.3%	3.25B▲ 37.3%	3.72B▲ 14.4%	4.63B▲ 24.5%	4.91B▲ 0%
Asset Turnover	0.20x	0.45x	0.60x	0.60x	0.55x	0.63x	0.58x	0.63x	0.62x	0.70x
Asset Growth %	123.94%	21.47%	31.5%	32.83%	19.47%	14.29%	37.27%	14.37%	24.55%	95.95%
Total Current Liabilities	54.43M	88.23M	565.3M	186.5M	245.8M	537.7M	654.8M	507.7M	743.4M	831.7M
Accounts Payable	5.65M	38.38M	41.4M	39.4M	51.5M	67.3M	133.3M	110M	104.9M	0
Days Payables Outstanding	1.64K	2.86K	2.04K	1.42K	1.31K	1.06K	1.23K	1.18K	734.9	530.12
Short-Term Debt	0	0	408.8M	0	0	169.4M	170.1M	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	25.81M	42.78M	84.7M	90.6M	133.3M	225.4M	261.4M	297.7M	423.9M	831.7M
Current Ratio	10.20x	8.36x	1.47x	5.45x	3.96x	2.70x	2.45x	3.40x	3.39x	3.39x
Quick Ratio	10.18x	8.24x	1.44x	5.30x	3.83x	2.64x	2.40x	3.28x	3.30x	3.30x
Cash Conversion Cycle	-1.28K	-2K	-1.13K	-357.16	-476.28	-420.78	-788.46	-490.43	-163.87	-30.45
Total Non-Current Liabilities	391.03M	424.15M	103.8M	422M	452.7M	123.2M	364.6M	621.3M	635M	667.1M
Long-Term Debt	369.62M	388.5M	0	317.9M	335.1M	0	0	0	0	406.2M
Capital Lease Obligations	0	0	86.7M	94.4M	105.3M	93.5M	258.3M	455.1M	415.3M	1.28B
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	11.18M	25.43M	17.1M	9.7M	12.3M	29.7M	106.3M	166.2M	219.7M	458M
Total Liabilities	445.45M	512.39M	669.1M	608.5M	698.5M	660.9M	1.02B	1.13B	1.38B	1.5B
Total Debt	369.62M	388.5M	495.5M	412.3M	440.4M	262.9M	428.4M	455.1M	415.3M	406.2M
Net Debt	114.91M	246.78M	383.2M	225.2M	99.6M	0	177.3M	222.1M	-297.7M	139.7M
Debt / Equity	0.99x	0.81x	0.78x	0.37x	0.32x	0.15x	0.19x	0.18x	0.13x	0.13x
Debt / EBITDA	-	9.52x	6.21x	2.40x	3.88x	0.99x	1.57x	0.76x	0.64x	0.50x
Net Debt / EBITDA	-	6.05x	4.80x	1.31x	0.88x	-	0.65x	0.37x	-0.46x	-0.46x
Interest Coverage	-6.30x	1.71x	2.45x	4.25x	4.93x	35.07x	85.83x	4.84x	-	-
Total Equity	372.14M▲ 0%	480.76M▲ 29.2%	636.9M▲ 32.5%	1.13B▲ 76.8%	1.37B▲ 22.0%	1.71B▲ 24.3%	2.23B▲ 30.7%	2.59B▲ 16.0%	3.25B▲ 25.6%	3.41B▲ 0%
Equity Growth %	18.19%	29.19%	32.48%	76.83%	22%	24.29%	30.69%	16.03%	25.62%	77.84%
Book Value per Share	4.22	5.04	6.65	11.52	14.03	17.27	22.10	24.97	31.74	32.95
Total Shareholders' Equity	372.14M	480.76M	636.9M	1.13B	1.37B	1.71B	2.23B	2.59B	3.25B	3.41B
Common Stock	89K	91K	92K	100K	100K	100K	100K	100K	100K	100K
Retained Earnings	-1.2B	-1.18B	-1.13B	-725.4M	-635.8M	-406.8M	-157.1M	29.2M	447.7M	589.6M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.85M	-1.93M	1.4M	1.8M	-1.7M	-7.9M	7M	5.8M	13.1M	400K
Minority Interest	0	0	0	0	0	0	0	0	0	0

NBIX Cash Flow Statement

Neurocrine Biosciences, Inc. (NBIX) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	-94.33M	101.4M	147M	228.5M	256.5M	339.4M	389.9M	595.4M	782.7M	782.7M
Operating CF Margin %	-58.36%	22.47%	18.65%	21.85%	22.63%	22.8%	20.66%	25.28%	27.36%	-
Operating CF Growth %	11.16%	207.49%	44.97%	55.44%	12.25%	32.32%	14.88%	52.71%	31.46%	287.05%
Net Income	-142.54M	21.1M	37M	407.3M	89.6M	154.5M	249.7M	341.3M	478.6M	668.6M
Depreciation & Amortization	2.4M	4M	7.4M	8.6M	10.9M	15.6M	21.3M	27.1M	30.1M	29.8M
Stock-Based Compensation	42.52M	58.1M	75.3M	100M	134.2M	173.1M	194.3M	195.5M	217.9M	222.3M
Deferred Taxes	0	0	0	-310.7M	4.3M	19.1M	-56.7M	-123.1M	165.4M	118M
Other Non-Cash Items	12.1M	19.9M	32.1M	61.2M	800K	44.5M	-46.9M	173.8M	19.5M	-317.9M
Working Capital Changes	-8.81M	-1.7M	-4.8M	-37.9M	16.7M	-67.4M	28.2M	-19.2M	-128.8M	142.9M
Change in Receivables	-31.13M	-25.1M	-69.2M	-30.5M	-28.4M	-162.2M	-89.3M	-39.8M	-210.5M	-255M
Change in Inventory	-1.02M	-3.5M	-6.4M	-10.7M	-2.5M	-2.6M	5.4M	-19.1M	-15.3M	-9.3M
Change in Payables	27.34M	0	0	26.9M	56.8M	114.6M	64.3M	29M	160.2M	133.5M
Cash from Investing	-251.25M	-242.9M	-211.1M	4.1M	-130.2M	-177.1M	-467.1M	-126.8M	-264.4M	-784.8M
Capital Expenditures	-6.94M	-24.8M	-14.7M	-10.9M	-23.4M	-16.5M	-28.3M	-38.2M	-34M	-32.4M
CapEx % of Revenue	4.29%	5.5%	1.87%	1.04%	2.06%	1.11%	1.5%	1.62%	1.19%	-
Acquisitions	0	0	0	0	0	-42.7M	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	7K	0	0	0	0	0	0	0	0	63.2M
Cash from Financing	516.65M	29.5M	32.4M	-157.8M	27.4M	-234.3M	65.3M	-486.7M	-38.3M	-6.5M
Debt Issued (Net)	502.78M	0	0	-186.9M	-100K	-279M	0	-308.8M	0	0
Equity Issued (Net)	13.87M	29.53M	27.31M	29.1M	27.5M	44.7M	65.3M	-177.9M	-38.3M	79.6M
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	-300M	-167.7M	-71.7M
Other Financing	0	-30K	5.09M	0	0	0	0	0	0	-86.1M
Net Change in Cash	171.06M▲ 0%	-112M▼ 165.5%	-31.7M▲ 71.7%	74.8M▲ 336.0%	153.7M▲ 105.5%	-73.3M▼ 147.7%	-11.6M▲ 84.2%	-18.1M▼ 56.0%	480M▲ 2751.9%	72.4M▲ 0%
Free Cash Flow	-101.27M▲ 0%	76.6M▲ 175.6%	132.3M▲ 72.7%	217.6M▲ 64.5%	233.1M▲ 7.1%	322.9M▲ 38.5%	361.6M▲ 12.0%	557.2M▲ 54.1%	748.7M▲ 34.4%	831.3M▲ 0%
FCF Margin %	-62.66%	16.98%	16.79%	20.8%	20.56%	21.69%	19.16%	23.66%	26.17%	26.8%
FCF Growth %	8.18%	175.64%	72.72%	64.47%	7.12%	38.52%	11.99%	54.09%	34.37%	68.89%
FCF per Share	-1.15	0.80	1.38	2.22	2.38	3.26	3.58	5.37	7.30	7.30
FCF Conversion (FCF/Net Income)	0.66x	4.80x	3.97x	0.56x	2.86x	2.20x	1.56x	1.74x	1.64x	1.24x
Interest Paid	0	0	11.6M	11.6M	8.6M	6.6M	3.8M	1.6M	0	0
Taxes Paid	0	0	500K	15.3M	5.1M	14.4M	51.5M	217.5M	81.4M	80.8M

NBIX Key Ratios

Neurocrine Biosciences, Inc. (NBIX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	-41.5%	4.95%	6.62%	46.2%	7.17%	10.03%	12.68%	14.16%	16.38%	21.64%
Return on Invested Capital (ROIC)	-27.42%	4.54%	6.21%	10.31%	5.44%	11.74%	9.14%	16.39%	16.1%	16.1%
Gross Margin	99.22%	98.91%	99.06%	99.03%	98.74%	98.44%	97.9%	98.56%	98.18%	98.17%
Net Margin	-88.19%	4.68%	4.69%	38.94%	7.9%	10.38%	13.23%	14.49%	16.73%	21.55%
Debt / Equity	0.99x	0.81x	0.78x	0.37x	0.32x	0.15x	0.19x	0.18x	0.13x	0.13x
Interest Coverage	-6.30x	1.71x	2.45x	4.25x	4.93x	35.07x	85.83x	4.84x	-	-
FCF Conversion	0.66x	4.80x	3.97x	0.56x	2.86x	2.20x	1.56x	1.74x	1.64x	1.24x
Revenue Growth	977.51%	179.16%	74.67%	32.71%	8.38%	31.34%	26.76%	24.81%	21.45%	28.59%

NBIX SEC Filings & Documents

Neurocrine Biosciences, Inc. (NBIX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 5, 2026·SEC

Material company update

Apr 6, 2026·SEC

Material company update

Feb 11, 2026·SEC

10-K Annual Reports

FY 2026

Feb 11, 2026·SEC

FY 2025

Feb 10, 2025·SEC

10-Q Quarterly Reports

FY 2026

May 5, 2026·SEC

FY 2025

Oct 28, 2025·SEC

FY 2025

Jul 30, 2025·SEC

NBIX Frequently Asked Questions

Neurocrine Biosciences, Inc. (NBIX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Neurocrine Biosciences, Inc. (NBIX) reported $3.10B in revenue for fiscal year 2025. This represents a 16058% increase from $19.2M in 1996.

Neurocrine Biosciences, Inc. (NBIX) grew revenue by 21.4% over the past year. This is strong growth.

Yes, Neurocrine Biosciences, Inc. (NBIX) is profitable, generating $668.6M in net income for fiscal year 2025 (16.7% net margin).

Dividend & Returns

Neurocrine Biosciences, Inc. (NBIX) has a return on equity (ROE) of 16.4%. This is reasonable for most industries.

Neurocrine Biosciences, Inc. (NBIX) generated $831.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More NBIX

Neurocrine Biosciences, Inc. (NBIX) financial analysis — history, returns, DCA and operating performance tools

Full NBIX Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Neurocrine Biosciences, Inc.(NBIX)Earnings, Financials & Key Ratios

NBIX Key Insights

✓Strengths

✗Weaknesses

NBIX Price & Volume

NBIX Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

NBIX Recent Earnings

NBIX Peer Comparison

Compare NBIX vs Peers

vs INVA

vs ABBV

Compare Top 5

NBIX Income Statement

NBIX Balance Sheet

NBIX Cash Flow Statement

NBIX Key Ratios

NBIX SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

NBIX Frequently Asked Questions

Explore More NBIX

Full NBIX Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation